Article Sidebar
Published:
Dec 30, 2022Keywords:
Article Details
Authors Retain Copyright
Authors retain the copyright of the manuscript they have published in the Journal of the Pan African Thoracic Society. The Authors grant Scientific Scholar an exclusive license to publish the article and the article is made available under the terms of a Creative Commons Attribution-Non-Commercial-Share Alike 4.0 License (CC-BY-NC-SA 4.0).
Open Access Publication and Creative Commons Licensing
Journal of the Pan African Thoracic Society is an open-access journal, and manuscripts published are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License (CC-BY-NC-SA 4.0), which allows others to remix, transform, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Compliance with Funder-Mandated Open Access Policies
An author whose work is funded by an organization that mandates the use of the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 License is able to meet that requirement through the available open-access license for approved funders.
Main Article Content
Clinical utility of serum procalcitonin in adult patients admitted with community-acquired pneumonia in Ilorin, Nigeria
Abstract
Objectives: The usefulness of biomarkers in community acquired pneumonia (CAP) has been under the research light with limited reports from Africa. This study aimed at evaluating the clinical usefulness of serum procalcitonin (PCT) in patients admitted with CAP in a tertiary hospital in Ilorin, Nigeria.
Materials and Methods: This was prospective single center observational study of 102 admitted patients with clinical and radiologic features of CAP. All the patients had serum PCT assay, complete blood count, blood culture, sputum microbiology, and serological evaluation for atypical pathogens. Repeat PCT assay was done following 1 week of antibiotic therapy. The patients were classified into one of two diagnostic groups: Those with microbiologically confirmed bacterial CAP and those without bacterial CAP.
Results: Over half (58/102; 56.8%) of the patients had microbiologically confirmed bacterial CAP. The baseline serum PCT concentrations were significantly higher in patients with bacterial CAP when compared to the non-bacterial CAP group (2.55 ± 0.14 vs. 0.94 ± 0.61 ng/ml; P < 0.001). There was also a statistically significant difference between the pre- and post-treatment serum PCT concentrations in the bacterial CAP group (P < 0.001) and the non-bacterial CAP group (P = 0.006). The area under the receiver operating characteristic (AUC) for pre-treatment PCT in diagnosing bacterial CAP was 0.795 (95% confidence level [CI]: 0.709–0.881) with a sensitivity of 67.2% and specificity of 79.5% at an optimal cutoff of 1.5 ng/ml. Overall, the biomarker was independently associated with white cell counts >10 × 109/L (AOR = 6.28; 95% CI: 1.30–30.32, P = 0.02). The baseline mean serum PCT levels were also significantly higher in patients admitted for 7 or more days (P = 0.010).
Conclusion: Serum PCT had good diagnostic strength in patients admitted with bacterial CAP in Ilorin. The biomarker can also assist clinicians with predicting the pathogenic group and monitoring clinical progress of CAP.
